MyFinsight
Home
Blog
About
Caribou Biosciences, Inc. (CRBU)
Caribou Biosciences, Inc. (CRBU)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$22,788K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from sales and maturiti...
Proceeds from issuances of commo...
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
External costs
Internal costs
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Licensing and other third-party revenue
1,499
2,397
3,941
2,198
External costs
9,566
10,690
14,445
12,285
Internal costs
7,641
8,179
7,612
8,364
Total research and development
17,207
18,869
22,057
20,649
General and administrative
6,530
6,802
6,916
7,389
Other segment items
3,101
3,006
3,656
3,560
Other income, net
1,057
1,195
2,200
11,402
Net loss
-24,282
-25,085
-26,488
-27,548
Depreciation and amortization
625
649
682
631
Gain (loss) on disposition of assets
0
-
0
0
Non cash consideration for licensing and collaboration revenue
0
-
0
0
Change in fair value of equity securities
0
0
-115
12
Stock-based compensation expense
2,477
2,357
2,738
2,931
Change in fair value of the mskcc success payments liability
0
0
0
0
Acquired in-process research and development
-
-
0
0
Accretion of discounts on investments in marketable securities, net
44
269
160
235
Asset, impairment loss
0
-
0
0
Impairment of equity method investment
0
-
0
0
Non-cash lease expense
321
315
422
457
Accounts receivable
-24
158
-173
171
Contract assets
-88
-315
146
107
Other receivables
-310
-459
76
-129
Prepaid expenses and other current assets
-52
-522
-2,403
-461
Other assets
50
-63
-1,609
155
Accounts payable
-423
-2,220
1,919
561
Accrued expenses and other current liabilities
-744
-2,646
-2,816
-1,111
Deferred revenue, current and long-term
-850
-1,005
-326
-627
Operating lease liabilities
-291
-281
-325
-389
Deferred tax liabilities
-
-
-548
-
Net cash used in operating activities
-22,787
-26,984
-20,824
-25,185
Proceeds from sales and maturities of marketable securities
39,445
46,142
61,788
68,414
Purchases of marketable securities
20,502
22,085
44,034
57,448
Purchases of property and equipment
1
72
-216
115
Proceeds from sale of property and equipment
-
-
0
-
Payments to acquire in-process research and development
-
-
0
0
Net cash provided by investing activities
18,942
23,985
17,970
10,851
Proceeds from exercise of stock options
12
9
0
0
Proceeds from issuances of common stock under espp
0
468
0
277
Proceeds from issuances of common stock related to atm, net of offering expenses
17,924
2,219
4,070
0
Net cash provided by financing activities
17,936
2,696
4,070
277
Net increase in cash, cash equivalents, and restricted cash
14,091
-303
1,216
-14,057
Cash, cash equivalents, and restricted cash beginning of period
12,103
12,406
11,190
16,339
Cash, cash equivalents, and restricted cash end of period
26,194
-
-
-
Cash and cash equivalents
26,194
-
-
-
Restricted cash
0
-
-
-
Cash, cash equivalents, and restricted cash on the balance sheet
26,194
12,103
12,406
11,190
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from sales and
maturities of marketable...
$39,445K
(-67.83%↓ Y/Y)
Proceeds from issuances
of common stock...
$17,924K
Proceeds from exercise of
stock options
$12K
(100.00%↑ Y/Y)
Net cash provided by
investing activities
$18,942K
(-74.20%↓ Y/Y)
Net cash provided by
financing activities
$17,936K
(3683.97%↑ Y/Y)
Canceled cashflow
$20,503K
Net increase in
cash, cash...
$14,091K
(58.18%↑ Y/Y)
Canceled cashflow
$22,787K
Purchases of marketable
securities
$20,502K
(-57.06%↓ Y/Y)
Purchases of property and
equipment
$1K
(-99.93%↓ Y/Y)
Stock-based compensation
expense
$2,477K
(-64.67%↓ Y/Y)
Depreciation and
amortization
$625K
(-73.20%↓ Y/Y)
Non-cash lease expense
$321K
(-66.74%↓ Y/Y)
Other receivables
-$310K
(-340.31%↓ Y/Y)
Contract assets
-$88K
(78.27%↑ Y/Y)
Prepaid expenses and
other current assets
-$52K
(93.59%↑ Y/Y)
Accounts receivable
-$24K
(87.63%↑ Y/Y)
Net cash used in
operating activities
-$22,787K
(64.93%↑ Y/Y)
Canceled cashflow
$3,897K
Licensing and other
third-party revenue
$1,499K
(-70.14%↓ Y/Y)
Other income, net
$1,057K
(122.14%↑ Y/Y)
Net loss
-$24,282K
(74.19%↑ Y/Y)
Canceled cashflow
$2,556K
Deferred revenue,
current and long-term
-$850K
(53.93%↑ Y/Y)
Accrued expenses and
other current...
-$744K
(69.17%↑ Y/Y)
Accounts payable
-$423K
(-154.65%↓ Y/Y)
Operating lease
liabilities
-$291K
(54.17%↑ Y/Y)
Other assets
$50K
(102.64%↑ Y/Y)
Accretion of discounts on
investments in marketable...
$44K
(-94.09%↓ Y/Y)
Total research and
development
$17,207K
(-70.38%↓ Y/Y)
General and
administrative
$6,530K
(-59.05%↓ Y/Y)
Other segment items
$3,101K
(-89.61%↓ Y/Y)
External costs
$9,566K
(-74.13%↓ Y/Y)
Internal costs
$7,641K
(-63.83%↓ Y/Y)
Buy us a coffee